Elementor #9193 | ERS Genomics

Welcome to ERS Genomics’ CRISPR/Cas9 Licensing Platform

Accessing cutting-edge genetic research tools shouldn’t be an uphill battle for startups. That’s why ERS Genomics, armed with the pioneering patent rights of Nobel Laureate Emmanuelle Charpentier, aims to simplify and expedite the process of acquiring CRISPR/Cas9 licenses. Our platform is designed to offer startups affordable and swift access to this groundbreaking technology for internal research purposes.

Facilitating Access to Genetic Innovation

We understand the challenges startups face when it comes to adopting transformative technologies. Our click license platform ensures startups can swiftly obtain CRISPR/Cas9 licenses at a fixed yearly fee, enabling immediate access to fundamental patent rights. By simplifying the licensing procedure, we eliminate unnecessary barriers, allowing startups to explore the potential of CRISPR/Cas9 without complex bureaucratic hurdles.

Cost

For startups keen on delving into genetic innovation, our program offers an accessible pathway. The program provides access to CRISPR/Cas9 licensing at a yearly fee of $15,000, ensuring startups can explore the potential of this revolutionary technology without financial strain or prolonged delays.

START-UP INTERNAL RESEARCH LICENSE APPLICATION

Eligibility Confirmation

Application Eligibility Criteria:
The following criteria serve as foundational requisites for determining the eligibility of a Start-Up entity seeking a license:

Size of the Start-Up:
The Start-Up should employ fewer than 15 individuals on a full-time basis.
Funding Limitation:
The Start-Up's total funding should not exceed $5,000,000 in financial resources.
Utilization of CRISPR:
The Start-Up either currently utilizes CRISPR technology or has explicit intentions to incorporate CRISPR within its operations.
Non-Commercialization of CRISPR:
The Start-Up must not engage in the commercialization of CRISPR technology at the present moment. This extends to the development, production, or provision of any products or services directly related to CRISPR.
Comprehensive Qualification:
Should the Start-Up affirmatively answer all the aforementioned questions, it shall be deemed qualified for consideration under the outlined eligibility criteria.

Does your company meet the specified criteria as outlined in the terms?

Company Information Company Name:

Billing Address:

Full-Time Employees (FTE):

Funding Status (if applicable):

Contact Information Contact Person's Name:

Role in the Company:

Email Address:

Phone Number:

Alternate Contact (if applicable) Name:

Role:

Email Address:

Phone Number:

Rate Your Experience How would you rate your experience navigating to the license platform on our website and accessing the necessary information? (1-10)

Additional Information Is there any further information or details you believe are important for us to consider during the review of your application?

Contact Request Speak to a member of out team prior to signing?

License Terms View Terms

START-UP INTERNAL RESEARCH LICENSE TERMS & AGREEMENTS

Background:

ERS Genomics Limited (“ERS”) holds exclusive worldwide rights (except for CRISPR-Cas9 used as a human therapeutic) under certain Patent Rights. Start-Up, meeting the criteria in Exhibit B, is engaged in discovery and research using these Patent Rights. Start-Up seeks a non-exclusive license from ERS for discovery and research, subject to the terms herein.

Definitions:

Confidential Information: Covers scientific, regulatory, marketing, financial, and commercial data shared under this Agreement.

CRISPR-Cas9: Genome editing tech using Cas9 or variants, along with guide RNAs, described in the Patent Rights.

Field: Encompasses making and using Modified Animals and Cells for internal research, excluding specific activities listed in detail.

Modified Animal/Cell: Genome or gene expression altered using CRISPR-Cas9.

License:

Grant: ERS grants Start-Up a non-exclusive, non-transferable, royalty-free license in the Field within the Territory.

Exclusions: Start-Up cannot practice Patent Rights outside the Field.

Sublicensing: Start-Up can't sublicense or conduct research activities with a Third Party unless that party has a license from ERS.

Fees:

Signature Fee: Start-Up pays ERS a one-time fee of $15,000 USD within 15 days of the Effective Date.

Annual Maintenance Fee: Start-Up pays ERS an annual fee of $15,000 USD on each anniversary of the Effective Date during the Term.

Payments:

All payments are in USD via wire transfer to ERS's designated bank unless specified otherwise.

Representations, Warranties, and Liability:

Start-Up represents its authorization to enter this Agreement and its enforceability.
ERS disclaims warranties regarding Patent Rights and the success of their exploitation.
ERS shall not be liable for certain indirect damages.

Confidentiality:

Parties must maintain confidentiality of shared information, except where exceptions apply.

Term; Termination:

The Term starts on the Effective Date and ends upon expiration of the last Valid Claim of the Patent Rights in the Territory.
Termination is possible by Start-Up or ERS for specified reasons outlined in the Agreement.

Indemnification:

Start-Up indemnifies ERS against specified losses arising from Start-Up’s actions under the Agreement.

Miscellaneous:

Notices, Entire Agreement, Assignment, Severability, Choice of Law, Counterparts, and other legal matters are detailed within the Agreement, to be signed.

Application Review & Compliance Confirmation Applicants must confirm their understanding and compliance with the license terms, criteria, and eligibility requirements as outlined below.